Form 4: Vertex Pharmaceuticals EVP, Chief Scientific Officer David Altshuler Reports Sale of 1,111 Shares

David Altshuler, EVP and Chief Scientific Officer of Vertex Pharmaceuticals, sold 1,111 shares of common stock on February 20, 2025, at a price of $480 per share, according to a Form 4 filing with the SEC.

Summary

• On February 20, 2025, David Altshuler, the EVP and Chief Scientific Officer of Vertex Pharmaceuticals, sold 1,111 shares of the company's common stock.
• The sale was executed at a price of $480 per share.
• Following the transaction, Altshuler directly owns 45,019 shares of Vertex Pharmaceuticals.
• The transaction was made pursuant to a pre-arranged trading plan under Rule 10b5-1, which was established on August 8, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine transaction under a pre-existing trading plan. It doesn't inherently indicate positive or negative prospects for the company.

Industry Context

Insider sales are a common occurrence and are often scrutinized by investors for insights into a company's prospects; however, sales under pre-arranged trading plans are generally viewed as less informative.

Stakeholder Impact

• The sale of shares by a high-ranking executive could be perceived negatively by some shareholders, although the existence of a pre-arranged trading plan mitigates this concern.

Key Dates